Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Drug harms in the UK: a multicriteria decision analysis
Improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs, however, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.
Development of a rational scale to assess the harm of drugs of potential misuse
The methodology developed and explored the feasibility of the use of a nine-category matrix of harm, with an expert delphic procedure, to assess the harms of a range of illicit drugs in an evidence-based fashion and yielded roughly similar scores and rankings of drug harm when used by two separate groups of experts.
Effects of Schedule I drug laws on neuroscience research and treatment innovation
An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses difficult and in many cases almost impossible.
The content of ecstasy tablets: implications for the study of their long-term effects.
The data from the north-west of England in 2001 indicate that the amount of MDMA in ecstasy tablets is dropping and that dose-effect relationships need to take this into account.
Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products.
- S. Hudson, J. Ramsey, +4 authors D. Wood
- Chemistry, MedicineJournal of analytical toxicology
- 1 June 2010
The application of high-resolution accurate mass spectrometry provides a relatively simple and quick method for screening products, building substance databases, and even identifying novel substances using a combination of accurate mass derived elemental composition and fragment ions combined with fragmentation prediction software.
The new drug phenomenon.
Cannabis potency in Europe.
Concerns about high potency cannabis are by no means new, and the reality appears both less alarming and more complex.
New phenethylamines in Europe.
- L. King
- Chemistry, MedicineDrug testing and analysis
- 1 July 2014
Sixteen phenethylamines are now included in Schedules I and II of the United Nations 1971 Convention on Psychotropic Substances. Most of the ring-substituted compounds are in Schedule I, whereas…
A brief history of 'new psychoactive substances'.